Literature DB >> 20713673

The initial 96 hours of invasive pulmonary aspergillosis: histopathology, comparative kinetics of galactomannan and (1->3) β-d-glucan and consequences of delayed antifungal therapy.

William W Hope1, Vidmantas Petraitis, Ruta Petraitiene, Tamarra Aghamolla, John Bacher, Thomas J Walsh.   

Abstract

Acute invasive pulmonary aspergillosis is a rapidly progressive and frequently lethal infection. Relatively little is known about early events in the pathogenesis and relationship between the cell wall biomarkers galactomannan and (1→3)-β-d-glucan. The consequences of delayed antifungal therapy are also poorly defined. A persistently neutropenic rabbit model of invasive pulmonary aspergillosis was used to describe the histopathology of early invasive pulmonary aspergillosis and the kinetics of galactomannan and (1→3)-β-d-glucan. The time course of both molecules was mathematically modeled by using a population methodology, and Monte Carlo simulations were performed. The effect of progressive delay in the administration of amphotericin B deoxycholate 1 mg/kg at 24, 48, 72, and 96 h postinoculation on fungal burden, lung weight, pulmonary infarct score, and survival was determined. Histopathology showed phagocytosis of conidia by pulmonary alveolar macrophages at 4 h postinoculation. At 12 to 24 h, there was a progressive focal inflammatory response with conidial germination and hyphal extension. Subsequently, hyphae invaded into the contiguous lung. Galactomannan and (1→3)-β-d-glucan had similar trajectories, and both exhibited considerable interindividual variability, which was reflected in Monte Carlo simulations. Concentrations of both molecules began to rise <24 h postinoculation before pulmonary hemorrhagic infarction was present. Delays of 72 and 96 h in the administration of amphotericin B resulted in fungal burdens and lung weights that were indistinguishable from those of controls, respectively. Galactomannan and (1→3)-β-d-glucan have similar kinetics and are comparable biomarkers of early invasive pulmonary aspergillosis. Antifungal treatment at ≥48 h postinoculation is associated with suboptimal therapeutic outcomes.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20713673      PMCID: PMC2976140          DOI: 10.1128/AAC.00673-10

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  20 in total

1.  Combination therapy in treatment of experimental pulmonary aspergillosis: synergistic interaction between an antifungal triazole and an echinocandin.

Authors:  Vidmantas Petraitis; Ruta Petraitiene; Alia A Sarafandi; Amy M Kelaher; Caron A Lyman; Heather E Casler; Tin Sein; Andreas H Groll; John Bacher; Nilo A Avila; Thomas J Walsh
Journal:  J Infect Dis       Date:  2003-06-04       Impact factor: 5.226

2.  Time to initiation of fluconazole therapy impacts mortality in patients with candidemia: a multi-institutional study.

Authors:  Kevin W Garey; Milind Rege; Manjunath P Pai; Dana E Mingo; Katie J Suda; Robin S Turpin; David T Bearden
Journal:  Clin Infect Dis       Date:  2006-05-16       Impact factor: 9.079

3.  Need for early antifungal treatment confirmed in experimental disseminated Candida albicans infection.

Authors:  Donna M MacCallum; Frank C Odds
Journal:  Antimicrob Agents Chemother       Date:  2004-12       Impact factor: 5.191

4.  Multicenter clinical evaluation of the (1-->3) beta-D-glucan assay as an aid to diagnosis of fungal infections in humans.

Authors:  Luis Ostrosky-Zeichner; Barbara D Alexander; Daniel H Kett; Jose Vazquez; Peter G Pappas; Fumihiro Saeki; Paul A Ketchum; John Wingard; Robert Schiff; Hiroshi Tamura; Malcolm A Finkelman; John H Rex
Journal:  Clin Infect Dis       Date:  2005-07-21       Impact factor: 9.079

5.  Intrapulmonary penetration of voriconazole in patients receiving an oral prophylactic regimen.

Authors:  Blair Capitano; Brian A Potoski; Shahid Husain; Shimin Zhang; David L Paterson; Sean M Studer; Kenneth R McCurry; Raman Venkataramanan
Journal:  Antimicrob Agents Chemother       Date:  2006-05       Impact factor: 5.191

6.  Efficacy of unilamellar liposomal amphotericin B in treatment of pulmonary aspergillosis in persistently granulocytopenic rabbits: the potential role of bronchoalveolar D-mannitol and serum galactomannan as markers of infection.

Authors:  P Francis; J W Lee; A Hoffman; J Peter; A Francesconi; J Bacher; J Shelhamer; P A Pizzo; T J Walsh
Journal:  J Infect Dis       Date:  1994-02       Impact factor: 5.226

7.  Antifungal activity and pharmacokinetics of posaconazole (SCH 56592) in treatment and prevention of experimental invasive pulmonary aspergillosis: correlation with galactomannan antigenemia.

Authors:  R Petraitiene; V Petraitis; A H Groll; T Sein; S Piscitelli; M Candelario; A Field-Ridley; N Avila; J Bacher; T J Walsh
Journal:  Antimicrob Agents Chemother       Date:  2001-03       Impact factor: 5.191

8.  Amphotericin B formulations exert additive antifungal activity in combination with pulmonary alveolar macrophages and polymorphonuclear leukocytes against Aspergillus fumigatus.

Authors:  Emmanuel Roilides; Caron A Lyman; Joanna Filioti; Onome Akpogheneta; Tin Sein; Cristina Gil Lamaignere; Ruta Petraitiene; Thomas J Walsh
Journal:  Antimicrob Agents Chemother       Date:  2002-06       Impact factor: 5.191

9.  Delaying the empiric treatment of candida bloodstream infection until positive blood culture results are obtained: a potential risk factor for hospital mortality.

Authors:  Matthew Morrell; Victoria J Fraser; Marin H Kollef
Journal:  Antimicrob Agents Chemother       Date:  2005-09       Impact factor: 5.191

10.  Compartmentalized intrapulmonary pharmacokinetics of amphotericin B and its lipid formulations.

Authors:  Andreas H Groll; Caron A Lyman; Vidmantas Petraitis; Ruta Petraitiene; Derek Armstrong; Diana Mickiene; Raul M Alfaro; Robert L Schaufele; Tin Sein; John Bacher; Thomas J Walsh
Journal:  Antimicrob Agents Chemother       Date:  2006-10       Impact factor: 5.191

View more
  26 in total

1.  Early diagnosis of invasive pulmonary aspergillosis in hematologic patients: an opportunity to improve the outcome.

Authors:  Marcio Nucci; Simone A Nouér; Domenico Cappone; Elias Anaissie
Journal:  Haematologica       Date:  2013-11       Impact factor: 9.941

Review 2.  Treatment principles for the management of mold infections.

Authors:  Dimitrios P Kontoyiannis; Russell E Lewis
Journal:  Cold Spring Harb Perspect Med       Date:  2014-11-06       Impact factor: 6.915

Review 3.  Prognostic value of galactomannan: current evidence for monitoring response to antifungal therapy in patients with invasive aspergillosis.

Authors:  Laura L Kovanda; Amit V Desai; William W Hope
Journal:  J Pharmacokinet Pharmacodyn       Date:  2017-02-08       Impact factor: 2.745

4.  Combination Therapy with Isavuconazole and Micafungin for Treatment of Experimental Invasive Pulmonary Aspergillosis.

Authors:  Vidmantas Petraitis; Ruta Petraitiene; Matthew W McCarthy; Laura L Kovanda; Myo H Zaw; Kaiser Hussain; Naima Shaikh; Bo Bo W Maung; Navjot K Sekhon; William W Hope; Thomas J Walsh
Journal:  Antimicrob Agents Chemother       Date:  2017-08-24       Impact factor: 5.191

5.  Pharmacodynamics of isavuconazole in experimental invasive pulmonary aspergillosis: implications for clinical breakpoints.

Authors:  Laura L Kovanda; Ruta Petraitiene; Vidmantas Petraitis; Thomas J Walsh; Amit Desai; Peter Bonate; William W Hope
Journal:  J Antimicrob Chemother       Date:  2016-04-15       Impact factor: 5.790

6.  Aerial prevalence of Aspergillus calidoustus isolates in and around a tertiary care hospital in Kuwait and assessment of their pathogenicity.

Authors:  Ziauddin Khan; Suhail Ahmad; Leena Joseph
Journal:  J Clin Microbiol       Date:  2014-06-11       Impact factor: 5.948

7.  Pharmacokinetic Modeling of Voriconazole To Develop an Alternative Dosing Regimen in Children.

Authors:  Andreas H Groll; Georg Hempel; Silke Gastine; Thomas Lehrnbecher; Carsten Müller; Fedja Farowski; Peter Bader; Judith Ullmann-Moskovits; Oliver A Cornely
Journal:  Antimicrob Agents Chemother       Date:  2017-12-21       Impact factor: 5.191

8.  Molecular detection and species-specific identification of medically important Aspergillus species by real-time PCR in experimental invasive pulmonary aspergillosis.

Authors:  Thomas J Walsh; Mark C Wissel; Kevin J Grantham; Ruta Petraitiene; Vidmantas Petraitis; Miki Kasai; Andrea Francesconi; Margaret P Cotton; Johanna E Hughes; Lora Greene; John D Bacher; Pradip Manna; Martin Salomoni; Steven B Kleiboeker; Sushruth K Reddy
Journal:  J Clin Microbiol       Date:  2011-10-05       Impact factor: 5.948

Review 9.  Aspergillus Species in Bronchiectasis: Challenges in the Cystic Fibrosis and Non-cystic Fibrosis Airways.

Authors:  Sanjay H Chotirmall; Maria Teresa Martin-Gomez
Journal:  Mycopathologia       Date:  2017-05-17       Impact factor: 2.574

10.  (1→3)-β-d-Glucan in Cerebrospinal Fluid as a Biomarker for Candida and Aspergillus Infections of the Central Nervous System in Pediatric Patients.

Authors:  Christine M Salvatore; Tempe K Chen; Sima S Toussi; Patricia DeLaMora; Ruta Petraitiene; Malcolm A Finkelman; Thomas J Walsh
Journal:  J Pediatric Infect Dis Soc       Date:  2015-03-19       Impact factor: 3.164

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.